Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cilostazol - Otsuka Pharmaceutical

Next Previous
X
Search
Drug Profile

Cilostazol - Otsuka Pharmaceutical

Alternative Names: OPC-13013; OPC-21; Pletaal; Pletal

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Otsuka Pharmaceutical
  • Developer Otsuka Pharmaceutical; Pfizer
  • Class Antiplatelets; Quinolines; Small molecules; Tetrazoles
  • Mechanism of Action Platelet aggregation inhibitors; Type 3 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Arterial occlusive disorders; Intermittent claudication; Stroke
  • Discontinued Angina pectoris; Coronary artery disease; Coronary artery restenosis

Most Recent Events

  • 13 Nov 2020 Otsuka Pharmaceutical completes phase I CiloMecT trial in Healthy volunteers (Adjunctive therapy) in Germany (PO) in March 2020 (EudraCT2013-002633-38) (NCT02554721)
  • 21 Sep 2017 No development reported - Phase-III for Angina pectoris (In the elderly, Treatment-experienced, In adults) in South Korea (PO)
  • 01 Jan 2016 Otsuka Pharmaceuticals completes the phase III STELLA_Ext trial for Vasospastic Angina in South Korea (NCT02094469)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top